利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

111 条记录 (耗时 0.03 秒)

    Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
    92.
    发明申请
    Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment 失效

    公开(公告)号：US20050196749A1

    公开(公告)日：2005-09-08

    申请号：US10403180

    申请日：2003-03-31

    申请人： James Young ,  Scott Koenig ,  Leslie Johnson ,  William Huse ,  Jeffrey Watkins ,  Herren Wu

    发明人： James Young ,  Scott Koenig ,  Leslie Johnson ,  William Huse ,  Jeffrey Watkins ,  Herren Wu

    IPC分类号： C07K16/10 ,  C12Q1/70 ,  C07K16/08

    CPC分类号： C07K16/1027 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

    摘要： The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection

    Humanization of antibodies
    93.
    发明申请
    Humanization of antibodies 审中-公开
    抗体的人源化

    公开(公告)号：US20050042664A1

    公开(公告)日：2005-02-24

    申请号：US10923068

    申请日：2004-08-20

    申请人： Herren Wu ,  William Dall-Acqua ,  Melissa Damschroder

    发明人： Herren Wu ,  William Dall-Acqua ,  Melissa Damschroder

    IPC分类号： C07K16/46 ,  C12Q1/68

    CPC分类号： C07K16/465

    摘要： The present invention provides methods of re-engineering or re-shaping an antibody from a first species, wherein the re-engineered or re-shaped antibody does not elicit undesired immune response in a second species, and the re-engineered or re-shaped antibody retains substantially the same antigen binding-ability of the antibody from the first species. In accordance with the present invention, a combinatorial library comprising the CDRs of the antibody from the first species fused in frame with framework regions derived from a second species can be constructed and screened for the desired modified antibody. In particular, the present invention provides methods utilizing low homology acceptor antibody frameworks for efficiently humanizing an antibody or a fragment thereof. The present invention also provides antibodies produced by the methods of the invention.

    摘要翻译： 本发明提供了重新设计或重新形成来自第一种类的抗体的方法，其中重新设计或重新形成的抗体在第二种物种中不引发不期望的免疫应答，并且重新设计或重新形成 抗体保留了来自第一物种的抗体基本相同的抗原结合能力。 根据本发明，可以构建包含来自与来自第二种类的框架区域框架融合的第一物种的抗体的CDR的组合文库，并筛选所需的修饰抗体。 特别地，本发明提供利用低同源受体抗体框架有效地使抗体或其片段人源化的方法。 本发明还提供通过本发明的方法制备的抗体。

    Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
    94.
    发明申请
    Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment 失效

    公开(公告)号：US20050002926A1

    公开(公告)日：2005-01-06

    申请号：US10900230

    申请日：2004-07-26

    申请人： James Young ,  Scott Koenig ,  Leslie Johnson ,  William Huse ,  Jeffrey Watkins ,  Herren Wu

    发明人： James Young ,  Scott Koenig ,  Leslie Johnson ,  William Huse ,  Jeffrey Watkins ,  Herren Wu

    IPC分类号： C07K16/10 ,  A61K39/395 ,  A61K39/42

    CPC分类号： C07K16/1027 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

    摘要： The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection

    Anti-&agr;v&bgr;3 recombinant human antibodies and nucleic acids encoding same
    95.
    发明授权
    Anti-&agr;v&bgr;3 recombinant human antibodies and nucleic acids encoding same 有权
    抗alphavbeta3重组人抗体和编码相同的核酸

    公开(公告)号：US06531580B1

    公开(公告)日：2003-03-11

    申请号：US09339922

    申请日：1999-06-24

    申请人： William D. Huse ,  Herren Wu

    发明人： William D. Huse ,  Herren Wu

    IPC分类号： C07K1628

    CPC分类号： C07K16/2848 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565

    摘要： The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to &agr;V&bgr;3, or a functional fragment thereof. The invention also provides nucleic acid molecules encoding the enhanced LM609 grafted antibodies. Additionally provided are methods of inhibiting a function of &agr;V&bgr;3 by contacting &agr;V&bgr;3 with an enhanced LM609 grafted antibody.

    摘要翻译： 本发明提供了对αVβ3显示选择性结合亲和力的增强的LM609接枝抗体或其功能性片段。 本发明还提供编码增强的LM609接枝抗体的核酸分子。 另外提供了通过使αVβ3与增强的LM609接枝抗体接触来抑制αVβ3的功能的方法。

    High affinity antibodies against HMGB1 and methods of use thereof
    98.
    发明授权
    High affinity antibodies against HMGB1 and methods of use thereof 失效
    针对HMGB1的高亲和力抗体及其使用方法

    公开(公告)号：US08153131B2

    公开(公告)日：2012-04-10

    申请号：US12534217

    申请日：2009-08-03

    申请人： Herren Wu ,  Christian Allan ,  Changshou Gao ,  Ling-Ling An ,  Peter Kiener ,  Su-Yau Mao ,  Anthony Coyle

    发明人： Herren Wu ,  Christian Allan ,  Changshou Gao ,  Ling-Ling An ,  Peter Kiener ,  Su-Yau Mao ,  Anthony Coyle

    IPC分类号： A61K39/395

    CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  Y02A50/412

    摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

    摘要翻译： 公开了用于抑制促炎细胞因子从脊椎动物细胞中释放并抑制患者炎性细胞因子级联的组合物和方法。 组合物包含例如特异性结合HMG1的高亲和力抗体及其抗原性片段。 本发明的高亲和力抗体和包含其的药物组合物可用于许多目的，例如作为针对广泛范围的炎性疾病和病症的治疗剂，例如败血症，类风湿性关节炎，腹膜炎，克罗恩病，再灌注损伤，败血症 内毒素性休克，囊性纤维化，心内膜炎，牛皮癣，牛皮癣关节炎，关节炎，过敏性休克，器官缺血，再灌注损伤和同种异体移植排斥。 此外，本发明的高亲和力抗体可用作诊断抗体。

    Modulation of antibody effector function by hinge domain engineering
    99.
    发明授权
    Modulation of antibody effector function by hinge domain engineering 有权
    通过铰链域工程调节抗体效应子功能

    公开(公告)号：US08008443B2

    公开(公告)日：2011-08-30

    申请号：US11912562

    申请日：2006-04-25

    申请人： William Dall'Acqua ,  Herren Wu ,  Melissa Damschroder ,  Jose Casa-Finet

    发明人： William Dall'Acqua ,  Herren Wu ,  Melissa Damschroder ,  Jose Casa-Finet

    IPC分类号： C07K16/00 ,  C12P21/08 ,  A61K38/00

    CPC分类号： C07K16/18 ,  C07K16/00 ,  C07K16/2866 ,  C07K2317/53 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734

    摘要： The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more FcγR and/or CIq. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.

    摘要翻译： 本发明涉及包含至少一个抗原结合区和Fc区的新分子（Fc变体），其还包含修饰的铰链，其改变Fc与一个或多个Fc配体（例如FcγR）的结合和/或调节效应子 功能。 更具体地，本发明提供了对一种或多种FcγR和/或C1q具有修饰的结合亲和力的Fc变体。 另外，Fc变体具有改变的抗体依赖性细胞介导的细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）活性。 本发明还提供了用于所述Fc变体的应用的方法和方案，特别是用于治疗目的。

    HINGE DOMAIN ENGINEERING
    100.
    发明申请
    HINGE DOMAIN ENGINEERING 审中-公开
    铰链工程

    公开(公告)号：US20110077383A1

    公开(公告)日：2011-03-31

    申请号：US12666331

    申请日：2008-07-02

    申请人： William Dall'Acqua ,  Herren Wu ,  Melissa Damschroder ,  Jose Casas-Finet ,  Raul Cachau

    发明人： William Dall'Acqua ,  Herren Wu ,  Melissa Damschroder ,  Jose Casas-Finet ,  Raul Cachau

    IPC分类号： C07K16/00

    CPC分类号： C07K16/00 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

    摘要： The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which improves stability and/or alters the binding of Fc to one or more metal ion and/or one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that are less susceptible to metal ion-mediated cleavage and/or have modified binding affinity to one or more FcγR and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. Furthermore, the modified hinge of the Fc variants retains a similar flexibility to the wild type hinge. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.

    摘要翻译： 本发明涉及包含至少一个抗原结合区和Fc区的新分子（Fc变体），其还包含修饰的铰链，其改进稳定性和/或改变Fc与一个或多个金属离子和/或一个或多个金属离子的结合 更多的Fc配体（例如FcγR）和/或调节效应子功能。 更具体地，本发明提供对金属离子介导的切割较不敏感和/或具有对一个或多个FcγR和/或C1q的修饰的结合亲和力的Fc变体。 另外，Fc变体具有改变的抗体依赖性细胞介导的细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）活性。 此外，Fc变体的修饰的铰链保持与野生型铰链相似的柔性。 本发明还提供了用于所述Fc变体的应用的方法和方案，特别是用于治疗目的。